摘要
腹主动脉瘤(AAA)是一种永久且不可逆的腹主动脉局部扩张性病变,其破裂病死率高达60%~70%。AAA腔内修复术凭借其临床安全性和有效性已经成为AAA的一线治疗方法,但其长期随访中的支架移位、内漏等并发症仍值得关注。“ENGAGE”是迄今最大的AAA腔内治疗的长期注册研究,笔者基于“ENGAGE”研究8年随访结果和相应的文献分析,系统介绍AAA腔内治疗现状及前景。
Abdominal aortic aneurysm(AAA)is a permanent and irreversible localized dilatation of the abdominal aorta with a mortality after rupture ranging from 60%to 70%.Endovascular abdominal aortic aneurysm repair(EVAR)has been considered as the first-line option for the treatment of AAA owing to its clinical safety and effectiveness.However,the occurrence of complications in long-term follow-up such as stent displacement and endoleak is still raising concern.To date,"ENGAGE"is the largest long-term registration study of endovascular treatment of AAA.Here,the authors,based on the 8-year follow-up results of the"ENGAGE"study and relevant literature analysis,systematically introduce the current situation and outlook of endovascular treatment of AAA.
作者
吴明炜
熊江
WU Mingwei;XIONG Jiang(Department of Vascular Surgery,Chinese PLA General Hospital,Beijing 100853,China)
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2022年第6期713-716,共4页
China Journal of General Surgery
基金
国家自然科学基金资助项目(82170498)
北京市自然科学基金资助项目(7212094)。
关键词
主动脉瘤
腹
血管内操作
支架
Aortic Aneurysm,Abdominal
Endovascular Procedures
Stents
